The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.
It seemed that troubled Nordic Nanovector ASA had secured its future through a merger with APIM Therapeutics AS but those hopes have been blown away after shareholders voted against a tie-up with the fellow Norwegian biotech.
The proposed merger announced last month came after a lengthy strategic review to plot a survival plan for Nordic Nanovector...
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
EFPIA says reforms make the continent less attractive for innovative firms.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
